Voyager Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Voyager Therapeutics, Inc. (VYGR) reported Increase (Decrease) in Accounts Receivable of $1.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- Voyager Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $1.44M, a 2719.61% increase year-over-year.
- Voyager Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$267.00K, a 324.37% decline year-over-year.
- Voyager Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$1.43M.
- Voyager Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $1.51M, a 89.39% decline year-over-year.
- Voyager Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $257.00K.
- Voyager Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$78.65M, a 198.12% decline from fiscal 2023.
- Voyager Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $80.15M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.17M 10-Q · filed 2026-08-06 | -$254.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$267.00K 10-Q · filed 2026-05-07 | -$1.69M derived: sum of 2 quarters · filed 2026-05-07 | -$180.00K derived: sum of 3 quarters · filed 2026-05-07 | -$129.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $87.00K derived: sum of 2 quarters · filed 2026-03-09 | $138.00K derived: sum of 3 quarters · filed 2026-08-06 | $257.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.56M derived: sum of 2 quarters · filed 2026-08-06 | $1.68M 10-Q · filed 2025-11-10 | -$12.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $170.00K 10-Q · filed 2026-08-06 | -$14.28M derived: sum of 3 quarters · filed 2026-08-06 | -$28.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $119.00K 10-Q · filed 2026-05-07 | -$14.33M derived: sum of 2 quarters · filed 2026-05-07 | -$79.00K derived: sum of 3 quarters · filed 2026-05-07 | $786.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$14.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$198.00K derived: sum of 2 quarters · filed 2026-03-09 | $667.00K derived: sum of 3 quarters · filed 2026-03-09 | -$78.65M 10-K · filed 2026-03-09 |
| 2024-09-30 | $14.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $15.12M derived: sum of 2 quarters · filed 2025-11-10 | -$64.20M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $865.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$78.45M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | -$79.31M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $80.15M 10-K · filed 2026-03-09 | |||
| 2023-03-31 | $25.00M 10-Q · filed 2024-05-13 | |||
| 2022-09-30 | $10.00M 10-Q · filed 2023-11-06 | |||
| 2019-09-30 | $479.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $2.30M 10-Q · filed 2019-11-06 | ||
| 2019-06-30 | $1.82M 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |